Division of GlaxoSmithKline PLC
Latest From Okairos AG
TNX-1600 joins two other candidates, including Phase III TNX-102 SL, in Tonix’s PTSD portfolio. CureVac and Yale partner on mRNA therapies for pulmonary disease.
Paying €210m for a company that only has preclinical programs may seem steep but BI is clearly impressed with the progress being made by its Austrian partner's lead candidate.
Boehringer Ingelheim more than doubled its venture fund from €100m to €250m, giving BI more access to early innovation via new capital, two new investment managers and a West Coast presence.
European biotech NousCom is making ready two multi-neoantigen containing vaccines that with a new round of VC funding should enter clinical studies in 2018, and that it hopes to combine with checkpoint inhibitors.
- Therapeutic Areas
- Infectious & Viral Diseases
- Okairos SRL
- Western Europe
- Parent & Subsidiaries
- GlaxoSmithKline PLC
- Senior Management
Riccardo Cortese, MD, PhD, CEO
Alfredo Nicosia, PhD, CSO
- Contact Info
Phone: (39) 06 97246470
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.